智策 CorporateLink
A Business Communications Specialist
企業推廣顧問

Press Release

GLOBAL Bio-Chem

GLOBAL BIO-CHEM REPORTS AN INTERIM REVENUE OF HK$1.0 BILLION FORGES COOPERATION TO PRODUCE HIGH VALUE-ADDED PRODUCTS

28 August 2026 – Global Bio-chem Technology Group Company Limited ("Global Bio-chem" or the "Company", stock code: 00809, together with its subsidiaries, the "Group") reported an unaudited consolidated revenue of approximately HK$1,003.8 million (2025: HK$1,186.0 million) for the six months ended 30 June 2026 (the "Period"), with a gross profit of approximately HK$2.9 million (2025: HK$161.2 million).

The Group's financial performance during the Period was affected by severe domestic competition resulting from anti-dumping duties and other measures imposed by the European Union ("EU") and the United States. Despite a significant decline in finance costs, the Group's net loss widened to approximately HK$206.9 million (2025: HK$154.7 million) due to downward adjustment in gross profit.

The Group's traditional amino acid products were severely hit by additional trade barriers and domestic competition. During the Period, the Group's sales volume of amino acids products reduced to 141,000 metric tonnes ("MT") (2025: 187,000 MT), which resulted in an approximately 18.4% increase in average production costs due to lower capacity utilisation. This coupled with an approximately 1.9% drop in average selling prices caused a swing from a gross profit of approximately HK$164.4 million in the same period last year to a gross loss of approximately HK$8.9 million for the Period.

To mitigate the impact, the Group had expanded its export to non-EU markets and broadened its product line to cover high value-added products. Meanwhile, the Group is enhancing operational efficiency by upgrading the boiler facilities at the production site of Changchun Dahe in order to lower production costs. Commercial production of the new boilers is expected to commence in the fourth quarter of 2026.

In addition, during the Period, the Group entered into a cooperation agreement with Shenzhou Biology & Technology Co., Ltd. (神舟生物科技有限責任公司), engaging the Group for the production of Coenzyme Q10 mycelium. The cooperation enables the Group to explore new markets and enhance its production techniques and efficiency. The Group's collaboration with a large enterprise with state-owned background is expected to expedite its business development and enhance its brand awareness in the People's Republic of China (the "PRC").

Looking forward, the Group will actively progress with the production of Coenzyme Q10 and strive to expand its production volume of Coenzyme Q10 to enhance market competitiveness in a challenging environment. At the same time, the Group will remain committed to safeguarding its market position and diversifying its product portfolio, developing high value-added products and exploring various bio-fermentation ingredients to achieve a balanced market presence. These initiatives are expected to reinforce the Group's competitiveness, broaden its market reach, and create new growth drivers.

About Global Bio-chem

Global Bio-chem (stock code: 00809.HK) has been listed on the Main Board of The Stock Exchange of Hong Kong Limited since 2001. The Group is principally engaged in the manufacture and sale, research and development of corn-based biochemical products in the PRC. The Company's production facilities are based in Jilin province in the PRC.

– End –

Issued by: Global Bio-chem Technology Group Company Limited
Through: CorporateLink Limited

Media Enquiry: CorporateLink Limited

Shiu Ka Yue	Tel: 2801 6198/ 9029 1865	Email: sky@corporatelink.com.hk
Zoe Mak	Tel: 2801 6090/ 6539 3300	Email: zoe@corporatelink.com.hk
Zilia Zheng	Tel: 2801 7393/ 5481 9812	Email: zilia@corporatelink.com.hk

Global Bio-chem's financial highlights

	For the six months ended 30 June		
	2026 (Unaudited)	2025 (Unaudited)	Change %
Revenue (HK$ million)	**1,003.8**	1,186.0	(15.4)
Gross profit (HK$ million)	**2.9**	161.2	(98.2)
Loss for the period (HK$ million)	**(206.9)**	(154.7)	N/A
Loss per share (HK$)		(Re-presented)	
Basic	**(0.12)**	(0.18)	N/A
Diluted	**(0.12)**	(0.18)	N/A